Talis Awarded $25M NIH Contract for Point-of-Care COVID-19 Testing

What You Should Know:

– Today, Talis Biomedical Corporation announced it has
been awarded a $25M contract from the National Institutes of Health (NIH) as
part of Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative as
well as another $100 million in additional financing.  

– The new funding will be used to scale manufacturing for
the launch of the Talis One™ diagnostic platform that provides rapid and highly
accurate detection of COVID-19 at points-of-care in 30 minutes or less.

– The Talis One System is a fast, easy-to-use, solution
that brings testing out of the lab and to the point of care. The technology
provides healthcare professionals with an entire clinical lab in the palm of
their hand and is intended for use in non-laboratory settings, such as
physicians’ offices, urgent care clinics, elder care/assisted living
facilities, cancer treatment and dialysis centers, and potentially the
workplace.

Talis Biomedical Corporation ,
a company dedicated to developing high-performance point-of-care diagnostic
tests for infectious diseases, today announced that it has secured a $25
million contract from the National Institutes of Health (NIH) for Phase 2
of its Rapid Acceleration of Diagnostics (RADx) initiative. Additionally, the
company has completed an additional financing of $100 million to scale
manufacturing for the launch of the Talis One™ diagnostic platform, which
provides rapid and highly accurate detection of COVID-19 at the
point-of-care. 

Accurate Point of Care COVID-19 Testing

 Today, patients are
often forced to endure days of waiting for lab results.  As a result, doctors may initiate unnecessary
isolation or empirical treatment based on incomplete information. This approach
is costly and can be harmful to patients. With COVID-19 cases
on the rise in many areas across the country, there is a tremendous need for
access to testing, especially in vulnerable populations where the spread of
COVID-19 infection can be devastating.   The Talis One System is a molecular diagnostic
platform developed to enable rapid, highly accurate point-of-care testing for
infectious diseases such as COVID-19.

Talis One COVID-19 Assays

The Talis One assays are based on a proprietary, highly
optimized nucleic acid isothermal amplification chemistry to achieve
exceptional test performance much faster than traditional PCR. The system is
designed for use in non-laboratory settings, such as physicians’ offices,
urgent care clinics, elder care/assisted living facilities, cancer treatment
and dialysis centers, and potentially the workplace.

COVID-19 is the first infectious disease that the Talis One
System will support. Future infectious...